GlassScriptPhysician profile
Eva M Martin
NPI 1659710283
$1,605.02
in general payments reported to CMS, 2019-2025
22 companies · $671 in 2025
The $671 reported for 2025 was more than what 86% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $301 · 2020: $35.36 · 2022: $37.15 · 2023: $267 · 2024: $294 · 2025: $671.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,231.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,231.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $220.42 | 2024-2025 | Veozah |
| Davol INC. | $193.10 | 2025 | Arista |
| Abbvie INC. | $182.29 | 2019-2025 | Liletta, Orilissa, Lo Loestrin Fe |
| Coopersurgical, INC. | $115.47 | 2019-2024 | Paragard T 380a, Paragard T 380a |
| Amgen INC. | $111.24 | 2025 | Evenity |
| Bayer Healthcare Pharmaceuticals INC. | $107.72 | 2019-2024 | |
| Shield Therapeutics INC | $80.62 | 2024 | |
| Conmed Corporation | $74.00 | 2019 | |
| Sumitomo Pharma America, INC. | $71.46 | 2024-2025 | Myfembree |
| Mayne Pharma Commercial LLC | $68.47 | 2023-2025 | |
| Exeltis, USA INC. | $68.32 | 2024-2025 | Slynd |
| Hologic Sales and Service, LLC | $52.59 | 2019-2024 | Aptima, Affirm Prone Biopsy System, Thinprep 2000 Processor |
| Sage Therapeutics, LLC | $52.25 | 2025 | Zurzuvae |
| Millicent US INC | $41.54 | 2025 | Intrarosa, Femring, Femlyv |
| Merck Sharp & Dohme LLC | $35.09 | 2019-2020 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $24.41 | 2023 | Nexplanon |
| Pfizer INC. | $23.59 | 2025 | |
| Lupin INC. | $21.36 | 2019 | |
| Baxter Healthcare | $19.41 | 2019 | |
| Ferring Pharmaceuticals INC. | $15.58 | 2019 | |
| Mylan Pharmaceuticals INC. | $13.49 | 2019 | |
| Amag Pharmaceuticals, INC. | $12.60 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eva Martin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.